UBS has reiterated its sell rating for Zur Rose Group AG, a Swiss pharmaceutical distribution company.

The company operates through two divisions: Zur Rose, which focuses on wholesale distribution of medicines to healthcare providers, and DocMorris, which specializes in mail-order pharmacy services.

Zur Rose Group AG serves a diverse clientele, including doctors, health insurers, hospitals, and other healthcare entities, primarily in Switzerland, Germany, and the Netherlands.

The company has several subsidiaries, including Zur Rose Suisse AG, Zur Rose Pharma GmbH, BlueCare AG, DocMorris NV, Eurapon Pharmahandel GmbH, and Vitalsana BV, which demonstrate its extensive presence in the European pharmaceutical market.